###begin article-title 0
Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression
###end article-title 0
###begin p 1
D.M. Altmann, C.M. Lloyd, and M. Larche contributed equally to this paper.
###end p 1
###begin p 2
###xml 762 763 762 763 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
###xml 122 125 <span type="species:ncbi:9685">cat</span>
###xml 538 543 <span type="species:ncbi:9606">human</span>
###xml 597 602 <span type="species:ncbi:10090">mouse</span>
###xml 1184 1189 <span type="species:ncbi:9606">human</span>
###xml 1213 1218 <span type="species:ncbi:10090">mouse</span>
###xml 1270 1276 <span type="species:ncbi:9606">humans</span>
Treatment of patients with allergic asthma using low doses of peptides containing T cell epitopes from Fel d 1, the major cat allergen, reduces allergic sensitization and improves surrogate markers of disease. Here, we demonstrate a key immunological mechanism, linked epitope suppression, associated with this therapeutic effect. Treatment with selected epitopes from a single allergen resulted in suppression of responses to other ("linked") epitopes within the same molecule. This phenomenon was induced after peptide immunotherapy in human asthmatic subjects and in a novel HLA-DR1 transgenic mouse model of asthma. Tracking of allergen-specific T cells using DR1 tetramers determined that suppression was associated with the induction of interleukin (IL)-10+ T cells that were more abundant than T cells specific for the single-treatment peptide and was reversed by anti-IL-10 receptor administration. Resolution of airway pathophysiology in this model was associated with reduced recruitment, proliferation, and effector function of allergen-specific Th2 cells. Our results provide, for the first time, in vivo evidence of linked epitope suppression and IL-10 induction in both human allergic disease and a mouse model designed to closely mimic peptide therapy in humans.
###end p 2
###begin p 3
###xml 226 247 226 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Oldfield et al., 2002</xref>
###xml 277 300 277 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">Alexander et al., 2005a</xref>
###xml 335 358 335 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">Alexander et al., 2005b</xref>
###xml 514 535 510 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">Oldfield et al., 2001</xref>
###xml 537 558 533 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Oldfield et al., 2002</xref>
###xml 695 708 691 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">Schwartz 2003</xref>
###xml 737 759 733 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">Sundstedt et al., 2003</xref>
###xml 761 792 757 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">Apostolou and Von Boehmer, 2004</xref>
###xml 904 924 900 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib41">Verhoef et al., 2005</xref>
In previous clinical studies, intradermal (i.d.) injection of allergen-derived peptides resulted in modulation of surrogate markers of disease in allergic asthma; early- and late-phase skin responses to allergen were reduced (Oldfield et al., 2002), along with nasal symptoms (Alexander et al., 2005a) and airway hyperreactivity (AHR; Alexander et al., 2005b). Peptide treatment suppressed allergen-specific T cell proliferation and production of IL-4, IL-13, and IFN-gamma, whereas IL-10 production was enhanced (Oldfield et al., 2001; Oldfield et al., 2002). The immunological mechanisms responsible have yet to be defined, but may include clonal deletion, induction of anergy (for review see Schwartz 2003), and/or active regulation (Sundstedt et al., 2003; Apostolou and Von Boehmer, 2004). We recently demonstrated induction of functional allergen-specific regulatory T cells after peptide therapy (Verhoef et al., 2005).
###end p 3
###begin p 4
###xml 361 377 361 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Felis domesticus</italic>
###xml 548 549 545 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 137 142 <span type="species:ncbi:9606">human</span>
###xml 347 359 <span type="species:ncbi:9685">domestic cat</span>
###xml 361 377 <span type="species:ncbi:9685">Felis domesticus</span>
###xml 419 424 <span type="species:ncbi:10090">mouse</span>
###xml 444 449 <span type="species:ncbi:9606">human</span>
###xml 520 525 <span type="species:ncbi:10090">mouse</span>
###xml 703 708 <span type="species:ncbi:9606">human</span>
###xml 858 863 <span type="species:ncbi:10090">mouse</span>
Our clinical studies have focused on peripheral blood responses to allergen before and after therapy. A limitation of studying asthmatic human subjects is that it is not possible to directly examine local allergen-specific T cell responses within lung tissue. To address this issue, we have developed a model of Fel d 1 (the major allergen of the domestic cat, Felis domesticus)-induced allergic lung inflammation in a mouse transgenic for the human MHC class II molecule (HLA-DR1; DRA/DRB1*0101) and lacking endogenous mouse MHC class II (H2-Abetao). We were thus able to investigate mechanisms of peptide therapy-induced immunomodulation using the same peptides and route of treatment as that used in human therapy. Low-dose (1 microg) peptide therapy was used, reflecting our current clinical practice, and was substantially lower than previously used in mouse models. Immunological mechanisms were investigated by analyzing T cell responses to treatment peptides and nontreatment peptides from the same allergen molecule and using MHC class II (HLA-DR1) tetramers.
###end p 4
###begin p 5
###xml 82 87 <span type="species:ncbi:9606">human</span>
###xml 92 97 <span type="species:ncbi:10090">mouse</span>
###xml 168 172 <span type="species:ncbi:10090">mice</span>
###xml 244 248 <span type="species:ncbi:10090">mice</span>
###xml 499 502 <span type="species:ncbi:9685">cat</span>
###xml 522 528 <span type="species:ncbi:9606">humans</span>
###xml 533 537 <span type="species:ncbi:10090">mice</span>
###xml 598 603 <span type="species:ncbi:10090">mouse</span>
Here, we provide evidence for the induction of linked epitope suppression in both human and mouse responses, together with substantial induction of IL-10 in T cells of mice, which was not limited to cells specific for the treatment peptide. In mice, reduced Th2 cell recruitment to the lung and suppressed effector cell function resulted in IL-10-dependent resolution of allergic lung inflammation, directly demonstrating treatment efficacy of peptide therapy in this model. The common responses to cat peptide therapy in humans and mice, as well as clear reduction in allergic inflammation in the mouse model, provide evidence that peptide therapy suppresses allergic asthma via induction of IL-10 and linked epitope suppression.
###end p 5
###begin title 6
RESULTS
###end title 6
###begin title 7
Peptide immunotherapy induces linked epitope suppression of antigen-specific responses in allergic asthmatic subjects
###end title 7
###begin p 8
###xml 622 643 622 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Oldfield et al., 2002</xref>
###xml 923 931 923 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 a</xref>
###xml 1120 1128 1120 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 b</xref>
###xml 1269 1277 1269 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 c</xref>
###xml 1616 1642 1612 1638 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mycobacterium tuberculosis</italic>
###xml 547 550 <span type="species:ncbi:9685">cat</span>
###xml 1616 1642 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
To determine the effect of Fel d 1 peptide therapy on responses to Fel d 1 peptides not included in the therapeutic cocktail, we examined ex vivo peptide-specific proliferative responses and cytokine production from PBMCs of peptide-treated allergic asthmatics. PBMC proliferative responses to each of 16 Fel d 1 peptides (12 peptides from a therapeutic peptide vaccine; "treatment peptides," and 4 Fel d 1 peptides not included in the vaccine; "non-treatment peptides") were assessed in a randomized, double-blind, placebo-controlled trial in 24 cat-allergic asthmatic subjects. Clinical outcomes are reported elsewhere (Oldfield et al., 2002). Responses to all 12 treatment peptides were significantly reduced in the 16 subjects receiving active treatment, but not in the 8 subjects receiving placebo. Strikingly, responses to the four nontreatment peptides were significantly reduced in the active treatment group only (Fig. 1 a). Cytokine secretion followed a similar pattern. IL-4 production to all peptides (treatment and nontreatment) was significantly reduced in the active treatment, but not the placebo group (Fig. 1 b). IL-13 responses were more variable, with those to 6/12 treatment peptides significantly reduced, together with all nontreatment peptides (Fig. 1 c). IFN-gamma responses were generally low but variable, with those to 9/12 treatment peptides significantly reduced, together with all nontreatment peptides (unpublished data). No significant changes in proliferative or cytokine responses to the control recall antigen (in a routinely vaccinated population) purified protein derivative of Mycobacterium tuberculosis were observed.
###end p 8
###begin p 9
###xml 0 92 0 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Peptide immunotherapy in cat allergic asthmatic subjects induces linked epitope suppression.</bold>
###xml 1488 1514 1488 1514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mycobacterium tuberculosis</italic>
###xml 25 28 <span type="species:ncbi:9685">cat</span>
###xml 285 288 <span type="species:ncbi:9685">cat</span>
###xml 1004 1007 <span type="species:ncbi:9685">cat</span>
###xml 1291 1294 <span type="species:ncbi:9685">cat</span>
###xml 1488 1514 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
Peptide immunotherapy in cat allergic asthmatic subjects induces linked epitope suppression. PBMCs were isolated before and after a randomized, double-blind, placebo-controlled trial of peptide immunotherapy and frozen. Cells were thawed and cultured with individual peptides and with cat allergen extract for 6 d before quantification of proliferation and cytokine release. Assays were performed once on both pre- and posttreatment samples. Peptides shown by number on the x axis correspond to amino acid sequences in chain 1 (peptides 1-7) and chain 2 (peptides 8-16) of Fel d 1 sequence as follows: 1:1-17, 2:12-28, 3:23-38, 4:29-45, 5:39-55, 6:48-63, 7:54-69, 8:1-16, 9:7-23, 10:20-35, 11:29-44, 12:40-55, 13:48-63, 14:56-71, 15:67-82, 16:77-92. (a) Proliferation data were normalized by conversion to stimulation index (SI; cpm for peptide/allergen culture divided by cpm of medium alone culture). Peptide immunotherapy resulted in statistically significant reductions in proliferative responses to cat allergen extract and to treatment peptides and nontreatment peptides (peptide number shown in shaded boxes). The response to each peptide is represented in paired bars. Pretreatment, open bars; posttreatment, filled bars. IL-4 (b) and IL-13 (c) production to individual peptides and cat allergen extract was reduced as indicated by statistical significance. No significant changes in proliferative or cytokine responses to the control antigen-purified protein derivative (PPD) of Mycobacterium tuberculosis were observed. Data are median, range, and interquartiles (box-and-whisker plot). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
###end p 9
###begin title 10
###xml 118 119 115 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
Peptide immunotherapy reduces lung inflammation and improves lung function in sensitized and rechallenged DR1-tg/Abetao mice
###end title 10
###begin p 11
###xml 327 328 324 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 562 570 559 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">[29&#8211;45],</sup>
###xml 769 775 766 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2</xref>
###xml 959 982 956 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">Alexander et al., 2005a</xref>
###xml 984 1007 981 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">Alexander et al., 2005b</xref>
###xml 1257 1265 1254 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 a</xref>
###xml 1303 1312 1300 1309 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 1531 1539 1528 1536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 b</xref>
###xml 1595 1602 1592 1599 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 1650 1658 1647 1655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 c</xref>
###xml 1676 1685 1673 1682 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 1851 1859 1848 1856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 d</xref>
###xml 1970 1978 1967 1975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 e</xref>
###xml 2024 2031 2021 2028 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 2033 2041 2030 2038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 f</xref>
###xml 2063 2070 2060 2067 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 2355 2362 2352 2359 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 2372 2381 2369 2378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 2396 2404 2393 2401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 g</xref>
###xml 2512 2519 2509 2516 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 2531 2539 2528 2536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 h</xref>
###xml 2597 2604 2594 2601 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 162 167 <span type="species:ncbi:10090">mouse</span>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
###xml 208 213 <span type="species:ncbi:9606">human</span>
###xml 240 245 <span type="species:ncbi:10090">mouse</span>
###xml 443 448 <span type="species:ncbi:9606">human</span>
###xml 515 518 <span type="species:ncbi:9685">cat</span>
###xml 755 758 <span type="species:ncbi:9685">cat</span>
###xml 1140 1145 <span type="species:ncbi:10090">mouse</span>
###xml 1153 1157 <span type="species:ncbi:10090">Mice</span>
###xml 1481 1485 <span type="species:ncbi:10090">mice</span>
###xml 1517 1520 <span type="species:ncbi:9685">cat</span>
###xml 1572 1576 <span type="species:ncbi:10090">mice</span>
###xml 1805 1810 <span type="species:ncbi:10090">mouse</span>
###xml 1845 1849 <span type="species:ncbi:10090">mice</span>
###xml 1874 1877 <span type="species:ncbi:9685">cat</span>
###xml 1901 1905 <span type="species:ncbi:10090">mice</span>
###xml 2390 2394 <span type="species:ncbi:10090">mice</span>
To investigate the cellular and molecular mechanisms leading to immunosuppression of allergic responses after peptide immunotherapy, we have developed a specific mouse model. We generated mice transgenic for human HLA DR1, but deficient in mouse MHC class II, thus MHC class II-mediated antigen presentation in the DR1-tg/Abetao model was restricted to HLA-DR1-binding peptides. We chose a dosing schedule that was similar to that used in our human study and used a single peptide (residues 29-45 of chain 1 of the cat allergen Fel d 1, referred to here as Feld1[29-45], which was also a component of the clinical vaccine) to induce tolerance in allergen-primed animals to subsequent inhaled challenge with an aqueous extract containing Fel d 1 and other cat proteins (Fig. 2; sensitization and treatment protocol). We have previously shown that peptide immunotherapy in allergic asthmatic subjects improves surrogate clinical markers of airway inflammation (Alexander et al., 2005a; Alexander et al., 2005b). Therefore, we determined whether the peptide immunotherapy schedule had a similar effect on lung inflammation and function in our mouse model. Mice that were sham sensitized but challenged with allergen did not exhibit any pulmonary inflammation (Fig. 3 a). Animals treated with the control HA(306-318) (residues 306-318 of influenza hemagglutinin) peptide showed extensive peribronchial and perivascular eosinophilic inflammatory infiltrates comparable to those seen in mice sensitized and challenged with cat allergen (Fig. 3 b and not depicted). In contrast, mice treated with Feld1(29-45) had substantially reduced airway inflammation (Fig. 3 c) compared with HA(306-318)-treated animals. Importantly, we could assess airway inflammation in both the lumen (by lavage) and lung tissue in the mouse model. Compared with unsensitized mice (Fig. 3 d), exposure to cat allergen in sensitized mice was marked by goblet cell hyperplasia and mucus hypersecretion (Fig. 3 e). This was reduced after treatment with Feld1(29-45) (Fig. 3 f). The effect of Feld1(29-45) treatment was reflected in relative levels of leukocytes in the lung lumen. Eosinophils made up >60% of the BAL inflammatory infiltrate, the remaining cells being macrophages, lymphocytes, and a few neutrophils. Total BAL leukocytes and eosinophils were significantly reduced in Feld1(29-45) versus HA(306-318)-treated mice (Fig. 3 g). Both total leukocytes and eosinophils were also significantly reduced in digested lung tissue after Feld1(29-45) treatment (Fig. 3 h). Thus, a single therapeutic i.d. administration of Feld1(29-45) was able to significantly reduce allergic lung inflammation in both airway lumen and tissue after allergen rechallenge weeks later.
###end p 11
###begin p 12
###xml 0 117 0 117 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Schematic protocol flow chart for cat allergen-induced airway disease and therapeutic treatment with Fel d 1 peptide.</bold>
###xml 165 166 162 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 387 394 372 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 401 410 386 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 34 37 <span type="species:ncbi:9685">cat</span>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 278 281 <span type="species:ncbi:9685">cat</span>
###xml 513 517 <span type="species:ncbi:10090">Mice</span>
###xml 541 544 <span type="species:ncbi:9685">cat</span>
###xml 616 620 <span type="species:ncbi:10090">mice</span>
###xml 687 691 <span type="species:ncbi:10090">mice</span>
Schematic protocol flow chart for cat allergen-induced airway disease and therapeutic treatment with Fel d 1 peptide. Airway inflammation was induced in DR1-tg/Abetao mice sensitized with 10 microg recombinant Fel d 1 in alum (days 0 and 14) and challenged i.n. with 250 microg cat allergen extract (days 22, 23, and 24). To induce tolerance, a single i.d. injection of 1 microg of Feld1(29-45) (or HA(306-318) as a DR1-binding control) was administered (day 25) after establishment of eosinophilic inflammation. Mice were rechallenged with cat allergen extract (days 59 and 60), lung function was analyzed, and the mice were sacrificed (day 61) for tissue harvest. Unsensitized control mice received PBS in alum and were challenged in the same manner as sensitized animals.
###end p 12
###begin p 13
###xml 0 84 0 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Peptide immunotherapy reduces allergic lung inflammation and improves lung function.</bold>
###xml 105 106 102 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 324 333 321 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 360 367 357 364 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 1172 1173 1161 1162 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 2012 2021 2001 2010 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 2054 2061 2043 2050 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 2116 2117 2103 2104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2207 2216 2194 2203 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 2227 2232 2214 2219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1</italic>
###xml 2227 2232 2214 2219 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>Feld1</italic></sup>
###xml 2260 2261 2247 2248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 261 264 <span type="species:ncbi:9685">cat</span>
###xml 283 287 <span type="species:ncbi:10090">Mice</span>
###xml 410 413 <span type="species:ncbi:9685">cat</span>
###xml 612 616 <span type="species:ncbi:10090">mice</span>
###xml 618 622 <span type="species:ncbi:10090">Mice</span>
###xml 660 663 <span type="species:ncbi:9685">cat</span>
###xml 1884 1888 <span type="species:ncbi:10090">mice</span>
###xml 1966 1970 <span type="species:ncbi:10090">mice</span>
###xml 2122 2126 <span type="species:ncbi:10090">mice</span>
###xml 2241 2245 <span type="species:ncbi:10090">mice</span>
Peptide immunotherapy reduces allergic lung inflammation and improves lung function. MHC II (DR1-tg/Abeta0) mice were sensitized with PBS (unsensitized control) or rFel d 1 in alum and allergic inflammation localized to the lung by repeated i.n. challenge with cat allergen extract. Mice were treated by i.d. injection of HA(306-318) (control peptide) or Feld1(29-45) (treatment peptide) and rechallenged with cat allergen extract (i.n.). Representative lung histology from unsensitized (a and d), allergen-sensitized control peptide-treated (b and e), and allergen-sensitized allergen peptide-treated (c and f) mice. Mice were sacrificed 24 h after the final cat allergen challenge. Paraffin-embedded lung was sectioned (4 microM) and stained with hematoxylin and eosin (a-c) or periodic acid schiff for detection of mucin (d-f). Representative sections are shown for each treatment group. Bar, 50 microm. Original magnification, 400x. (g) Airways were lavaged with PBS via a tracheal cannula. BAL cells were transferred to slides by cytocentrifugation and differential cell counts were performed by counting eight high power fields (40x magnification; total area, 0.5 mm2 per area randomly selected) and dividing this number by the total number of cells per high power field. To obtain absolute numbers of each leukocyte subtype, percentages were multiplied by the total number of cells obtained in the lavage fluid. (h) Single lobes of lung tissue were digested with collagenase and DNase as described in the Materials and methods. Differential counts were performed on cytocentrifuge preparations as for BAL. (i) AHR was measured at day 60 by whole-body plethysmography in response to inhaled methacholine (3-100 mg/ml) for 1 min. Penh data were confirmed by direct measurement of airway resistance (RL; j) and lung dynamic compliance (Cdyn; k) in anesthetized and tracheotomized mice in response to inhaled methacholine (3-100 mg/ml). For i and j, Unsensitized mice are represented by squares, sensitized/HA(306-318) by circles, and sensitized/Feld1(29-45) by triangles. All data are expressed as mean +/- SEM. n = 6 mice/group. Two independent experiments were performed. *, P < 0.05 for sensitized HA(306-318) versus DR1Feld1-treated mice, Mann-Whitney U test.
###end p 13
###begin p 14
###xml 143 144 140 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 639 648 636 645 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 657 664 654 661 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 733 740 730 737 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 858 866 855 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 i</xref>
###xml 978 993 975 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, j and k</xref>
###xml 1063 1070 1060 1067 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 107 110 <span type="species:ncbi:9685">cat</span>
###xml 145 149 <span type="species:ncbi:10090">mice</span>
###xml 372 376 <span type="species:ncbi:10090">mice</span>
###xml 427 430 <span type="species:ncbi:9685">Cat</span>
###xml 852 856 <span type="species:ncbi:10090">mice</span>
To determine whether the reduction in bronchial inflammation was associated with improved lung function in cat allergen-sensitized DR1-tg/Abetao mice, we measured AHR to methacholine by whole body plethysmography 24 h after the first allergen rechallenge (d59) in addition to direct measurements of lung airway resistance and dynamic compliance in mechanically ventilated mice 24 h after the second allergen rechallenge (d60). Cat allergen sensitization and challenge resulted in airway inflammation and a methacholine dose-dependent increase in enhanced pause (Penh) at day 24 (unpublished data). Animals were subsequently treated with HA(306-318) or Feld1(29-45) and rechallenged with allergen 4 wk later. i.d. treatment with Feld1(29-45) significantly reduced Penh responses at 30 and 100 mg/ml methacholine doses to levels observed in unsensitized mice (Fig. 3 i). These data were confirmed by lung resistance and compliance measurements at the 100 mg/ml methacholine dose (Fig. 3, j and k). Thus, the reduction in cellular and tissue inflammation after Feld1(29-45) therapy was associated with a significant improvement in lung function.
###end p 14
###begin title 15
###xml 101 106 <span type="species:ncbi:10090">mouse</span>
Peptide immunotherapy induces linked epitope suppression of antigen-specific T cell responses in the mouse lung
###end title 15
###begin p 16
###xml 288 300 288 300 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1[29&#8211;45]</sub>
###xml 422 423 422 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 706 713 706 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 731 740 731 740 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 854 866 854 866 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1(29&#8211;45)</sub>
###xml 897 904 897 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 940 941 940 941 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 944 956 944 956 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1(29&#8211;45)</sub>
###xml 964 965 964 965 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 973 981 973 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 a</xref>
###xml 989 996 989 996 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 1056 1064 1056 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 b</xref>
###xml 1312 1319 1312 1319 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
###xml 211 215 <span type="species:ncbi:10090">mice</span>
###xml 767 771 <span type="species:ncbi:10090">mice</span>
###xml 1091 1095 <span type="species:ncbi:10090">mice</span>
###xml 1217 1221 <span type="species:ncbi:10090">mice</span>
To investigate the mechanisms behind the effect of peptide immunotherapy on allergic pathophysiology, we studied specific T cell responses in the lungs of treated and untreated mice. Because we were using DR1tg mice we could use an HLA-DR tetramer incorporating the treatment peptide (DR1Feld1[29-45]tetramer) to track allergen-specific cells in the lung and to study specific responses to allergen. The number of tetramer+ cells in the lungs was small. Therefore, to generate a detectable amount of cells, samples within each group were pooled and restimulated with recombinant Fel d 1 (rFel d 1) protein in vitro. Cells were labeled with CFSE to evaluate antigen-specific proliferative responses in Feld1(29-45)-treated versus HA(306-318) (control peptide)-treated mice. Representative data plots of lung tissue digest cultures stained with CD4 and DR1Feld1(29-45)tetramer demonstrate that Feld1(29-45) treatment reduced the number of CD4+DR1Feld1(29-45)tetramer+ cells (Fig. 4 a). Feld1(29-45) treatment reduced antigen-driven lymphocyte proliferation (Fig. 4 b). Cells from unsensitized mice did not proliferate in response to rFel d 1. In contrast, cells from sensitized, challenged, and control peptide-treated mice demonstrated substantial proliferation to rFel d 1, which was markedly reduced after Feld1(29-45) treatment.
###end p 16
###begin p 17
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Peptide immunotherapy reduces proliferative responses to Fel d 1.</bold>
###xml 331 343 331 343 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1[29&#8211;45]</sub>
###xml 378 380 378 380 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A2</sub>
###xml 429 441 429 441 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1(29&#8211;45)</sub>
###xml 555 564 555 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 613 620 613 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 798 805 798 805 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 881 888 881 888 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 997 999 997 999 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A2</sub>
###xml 1087 1099 1087 1099 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1(29&#8211;45)</sub>
###xml 1176 1177 1176 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 66 70 <span type="species:ncbi:10090">Mice</span>
###xml 182 186 <span type="species:ncbi:10090">mice</span>
###xml 590 594 <span type="species:ncbi:10090">mice</span>
###xml 814 818 <span type="species:ncbi:10090">mice</span>
Peptide immunotherapy reduces proliferative responses to Fel d 1. Mice were sacrificed at day 61 and cells from collagenase digests of lung tissue (cells pooled/treatment group of 6 mice) were labeled with CFSE and restimulated with Fel d 1 for 6 d. Cells were stained with HLA-DR1 tetramers specific for the treatment peptide (DR1Feld1[29-45]tetramer) or a control peptide (DR1A2tetramer) and analyzed by flow cytometry. (a) DR1Feld1(29-45)tetramer and CD4 double staining of cells from unsensitized (left), sensitized and treated with control peptide HA(306-318) (middle), and sensitized mice treated with Feld1(29-45) (right). (b) CFSE dilution analysis of total lymphocyte population (defined by scatter) in cells from unsensitized (left), sensitized control peptide-treated (middle), and Feld1(29-45)-treated mice (right). (c) CFSE dilution analysis of treatment peptide Feld1(29-45)-specific cells. (top row) Proliferation of CFSE-labeled lung digest cells labeled with control tetramer (DR1A2tetramer). (bottom row) Proliferation of CFSE-labeled lung digest cells labeled with DR1Feld1(29-45)tetramer. Representative plots are shown from three independent experiments. n = 6/group.
###end p 17
###begin p 18
###xml 77 84 77 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 137 145 137 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)+</sup>
###xml 155 165 155 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)neg</sup>
###xml 540 541 540 541 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 613 616 613 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 797 804 797 804 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 829 841 829 841 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1(29&#8211;45)</sub>
###xml 849 850 849 850 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 864 876 864 876 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1(29&#8211;45)</sub>
###xml 884 887 884 887 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 953 961 953 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 c</xref>
###xml 1024 1026 1024 1026 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A2</sub>
###xml 1087 1095 1087 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 c</xref>
###xml 1127 1135 1127 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 c</xref>
###xml 1170 1182 1170 1182 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1(29&#8211;45)</sub>
###xml 1300 1307 1300 1307 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 1395 1402 1395 1402 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 1421 1433 1421 1433 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1(29&#8211;45)</sub>
###xml 1441 1442 1441 1442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1462 1470 1462 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 c</xref>
###xml 1547 1559 1547 1559 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1(29&#8211;45)</sub>
###xml 1567 1570 1567 1570 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 1595 1603 1595 1603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 c</xref>
###xml 56 59 <span type="species:ncbi:9685">cat</span>
###xml 1121 1125 <span type="species:ncbi:10090">mice</span>
###xml 1272 1276 <span type="species:ncbi:10090">mice</span>
To determine a mechanistic link between amelioration of cat allergy and Feld1(29-45) treatment, we examined relative populations of Feld1(29-45)+ and Feld1(29-45)neg cells (i.e., T cells specific for the treatment peptide and T cells specific for other Fel d 1 epitopes, respectively) in ex vivo cell cultures stained with CFSE and stimulated with whole rFel d 1. The combination of CFSE and tetramer staining of allergen-stimulated cells allowed us to identify allergen-specific cycling cells that were treatment peptide-specific (tetramer+) and those specific for other Fel d 1 DR1-restricted epitopes (tetramerneg). We were thus able to visualize the effect of treatment with a single epitope on the T cell response to other epitopes in the same molecule (linked epitopes). Treatment with Feld1(29-45) decreased numbers of DR1Feld1(29-45)tetramer+ cells and DR1Feld1(29-45)tetramerneg cells proliferating to other DR1-restricted epitopes of Fel d 1 (Fig. 4 c). No staining of cells was observed with control tetramer (DR1A2tetramer, which contained a DR1-binding peptide from HLA-A2; Fig. 4 c, top) or in unsensitized mice (Fig. 4 c, left). Staining of cells with DR1Feld1(29-45)tetramer demonstrated that a proportion of proliferating cells in control peptide-treated mice were specific for Feld1(29-45). Their numbers were unaffected by control peptide treatment. After treatment with Feld1(29-45), the number of DR1Feld1(29-45)tetramer+ cells was reduced (Fig. 4 c, bottom right versus middle). Furthermore, the proliferative response of DR1Feld1(29-45)tetramerneg cells was also reduced (Fig. 4 c, bottom). This is indicative of active regulation through the induction of linked suppression (intramolecular tolerance) because treatment targeting T cells specific for one epitope of a molecule down-regulated the response to other epitopes.
###end p 18
###begin p 19
###xml 77 89 77 89 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1(29&#8211;45)</sub>
###xml 97 98 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 398 410 398 410 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1(29&#8211;45)</sub>
###xml 418 419 418 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 517 523 517 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5</xref>
###xml 599 606 599 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 558 573 <span type="species:ncbi:10090">transgenic mice</span>
Another important observation from this experiment is that no increase in DR1Feld1(29-45)tetramer+ noncycling cells was observed, suggesting that induction of anergy in airway T cells was not a contributing mechanism in this model. The possibility that these cells had trafficked to draining lymph nodes was investigated by tetramer staining of cell suspensions. Strikingly, there were very few DR1Feld1(29-45)tetramer+ cells in restimulated draining lymph node cell cultures compared with lung tissue cell cultures (Fig. 5). Collectively, these data in DR1 transgenic mice provide evidence of Feld1(29-45) treatment-induced linked epitope suppression associated with largely resolved lung inflammation and improved lung function.
###end p 19
###begin p 20
###xml 0 102 0 102 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lung tissue digests, but not draining lymph nodes, contain T cells specific for the treatment peptide.</bold>
###xml 330 342 330 342 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1[29&#8211;45]</sub>
###xml 377 379 377 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A2</sub>
###xml 502 503 502 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 103 107 <span type="species:ncbi:10090">Mice</span>
###xml 508 512 <span type="species:ncbi:10090">mice</span>
Lung tissue digests, but not draining lymph nodes, contain T cells specific for the treatment peptide. Mice were sacrificed at day 61 and cells from draining lymph nodes and collagenase digests of lung tissue were restimulated with Fel d 1 for 6 d. Cells were stained with HLA-DR1 tetramers specific for the treatment peptide (DR1Feld1[29-45]tetramer) or a control peptide (DR1A2tetramer; not depicted) and analyzed by flow cytometry. Representative plots are shown from three independent experiments. n = 6 mice/group.
###end p 20
###begin title 21
###xml 52 53 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 0 3 <span type="species:ncbi:9685">Cat</span>
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Cat allergen-sensitized and -challenged DR1-tg/Abetao mice demonstrate increased IL-10 after peptide immunotherapy, but no change in TGF-beta or Foxp3
###end title 21
###begin p 22
###xml 331 352 325 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Oldfield et al., 2002</xref>
###xml 354 372 348 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">Tarzi et al., 2006</xref>
###xml 380 387 374 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 539 554 533 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6, a and b</xref>
###xml 645 646 639 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 829 836 823 830 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 883 884 877 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 888 889 882 883 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 905 906 899 900 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 954 969 948 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6, c and d</xref>
###xml 1007 1008 1001 1002 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1069 1076 1063 1070 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 1116 1123 1110 1117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 1177 1178 1171 1172 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1284 1290 1266 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4</xref>
###xml 224 229 <span type="species:ncbi:10090">mouse</span>
###xml 239 242 <span type="species:ncbi:9685">cat</span>
###xml 302 307 <span type="species:ncbi:9606">human</span>
###xml 410 414 <span type="species:ncbi:10090">mice</span>
###xml 792 796 <span type="species:ncbi:10090">Mice</span>
###xml 948 952 <span type="species:ncbi:10090">mice</span>
Previous studies have implicated IL-10 and TGF-beta as important mediators in the regulation of in vivo immune responses; therefore, we investigated whether IL-10 or TGF-beta expression were associated with tolerance in our mouse model of cat allergy. We have previously reported induction of IL-10 in human peptide immunotherapy (Oldfield et al., 2002; Tarzi et al., 2006). Feld1(29-45) treatment in allergic mice was associated with a significant increase in IL-10 protein in bronchoalveolar lavage (BAL) and homogenates of lung tissue (Fig. 6, a and b). As IL-10 can be produced by many cell types, we determined whether allergen-specific CD4+ T cells contributed to increased IL-10 production. Lung tissue digest cells were cultured with rFel d 1 in vitro for 6 d, and then restimulated. Mice that had been treated with Feld1(29-45) had a significantly higher proportion of IL-10+ CD4+ cells and IL-10+ lymphocytes than control peptide-treated mice (Fig. 6, c and d). A substantial proportion of all CD4+ cells and lymphocytes stained positive for IL-10 after Feld1(29-45) treatment (>10%), indicating that Feld1(29-45) treatment induced a population of IL-10-producing CD4+ T cells that was much larger than the pool of cells specific for the treatment peptide (approximately2%; Fig. 4).
###end p 22
###begin p 23
###xml 0 114 0 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Peptide immunotherapy is associated with increased IL-10 production, but no role is evident for TGF-&#946; or Foxp3.</bold>
###xml 429 430 426 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 627 628 621 622 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 687 688 681 682 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 928 935 922 929 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 1008 1009 1002 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 115 119 <span type="species:ncbi:10090">Mice</span>
###xml 820 824 <span type="species:ncbi:10090">mice</span>
###xml 944 948 <span type="species:ncbi:10090">mice</span>
###xml 1084 1088 <span type="species:ncbi:10090">mice</span>
Peptide immunotherapy is associated with increased IL-10 production, but no role is evident for TGF-beta or Foxp3. Mice were sacrificed at day 61 and subjected to BAL. Individual lobes of lung tissue were enzymatically digested to release inflammatory cells. (a) IL-10 levels in BAL fluid were quantified by ELISA. (b) IL-10 levels in lung digest homogenates (100 mg of tissue) were quantified by ELISA. (c) The percentage of CD4+ cells within lung tissue digests expressing IL-10 was detected by flow cytometry. (d) The percentage of total lymphocytes within lung tissue digests expressing IL-10. (e) Levels of active TGF-beta1 were measured in BAL by ELISA. (f) Foxp3 expression in CD4+ lung tissue digest cells was measured by flow cytometry. For all graphs, white bars represent responses of cells from unsensitized mice and black bars and gray bars represent responses of sensitized HA(306-318)-treated and sensitized Feld1(29-45)-treated mice, respectively. P values were determined using Mann-Whitney U test. Mean data +/- SEM from three independent experiments each with five mice per group.
###end p 23
###begin p 24
###xml 79 86 76 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 138 146 132 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 e</xref>
###xml 223 224 214 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 432 433 423 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 503 504 494 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 508 509 499 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 526 533 517 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 558 567 549 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 582 590 573 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 f</xref>
###xml 576 580 <span type="species:ncbi:10090">mice</span>
Active TGF-beta was measured by ELISA in BAL and lung tissue homogenates. Feld1(29-45) treatment had no effect on active TGF-beta levels (Fig. 6 e; BAL data shown). TGF-beta was not detectable by flow cytometry in or on CD4+ T cells (not depicted). Foxp3 has been described as marker of regulatory T cells, and we were indeed able to detect intracellular Foxp3 expression in lung tissue digest, BAL, and peribronchial lymph node CD4+ cells. However, there was no significant increase in numbers of Foxp3+ CD4+ cells from Feld1(29-45)-treated compared with HA(306-318)-treated mice (Fig. 6 f; data for lung tissue cells shown).
###end p 24
###begin title 25
###xml 68 72 <span type="species:ncbi:10090">mice</span>
Pulmonary and systemic Th2 responses are reduced in peptide-treated mice
###end title 25
###begin p 26
###xml 150 168 150 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">Coyle et al., 1999</xref>
###xml 383 389 383 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7</xref>
###xml 467 468 467 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 573 579 573 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8</xref>
###xml 876 885 872 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 894 901 890 897 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 939 945 935 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2</xref>
###xml 1085 1094 1081 1090 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 1114 1121 1110 1117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 1246 1261 1242 1257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig9">Fig. 9, a and b</xref>
###xml 1365 1372 1357 1364 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 1607 1629 1599 1621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">Daugherty et al., 1996</xref>
###xml 1631 1652 1623 1644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">Sallusto et al., 1997</xref>
###xml 1654 1672 1646 1664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Lloyd et al., 2000</xref>
###xml 1767 1772 1759 1764 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1</sub>
###xml 1767 1772 1759 1764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>Feld1</sub></italic>
###xml 1872 1879 1864 1871 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 1987 1996 1979 1988 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 2008 2023 2000 2015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig9">Fig. 9, c and d</xref>
###xml 2117 2118 2106 2107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 2237 2244 2226 2233 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 2255 2264 2244 2253 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 2315 2330 2304 2319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig9">Fig. 9, e and f</xref>
###xml 2364 2371 2353 2360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 856 860 <span type="species:ncbi:10090">mice</span>
###xml 1103 1107 <span type="species:ncbi:10090">mice</span>
###xml 1746 1750 <span type="species:ncbi:10090">mice</span>
###xml 1841 1845 <span type="species:ncbi:10090">mice</span>
###xml 2211 2215 <span type="species:ncbi:10090">mice</span>
###xml 2426 2429 <span type="species:ncbi:9685">cat</span>
Peptide immunotherapy was associated with an improvement in allergen-driven inflammation and lung function, both of which are dependent on Th2 cells (Coyle et al., 1999). Therefore, we assessed the effect of peptide treatment on Th2 function and recruitment. Peptide immunotherapy was associated with significantly decreased recruitment of Th2 cells in BAL and digested lung tissue (Fig. 7), although recruitment to draining lymph nodes was unaffected. Numbers of CD4+ T cells synthesizing IL-4 or IL-5 were significantly reduced in lung tissue digest cells after therapy (Fig. 8). Interestingly, no recruitment of these cells was seen in draining lymph nodes after allergen sensitization and challenge. We measured Th2 cytokines (IL-4, IL-5, and IL-13) and the Th1 cytokine IFN-gamma in BAL and in digested lung homogenates of unsensitized and sensitized mice treated with HA(306-318) or Feld1(29-45) before inhaled allergen rechallenge (Fig. 2). Allergen sensitization resulted in significant elevation of Th2 cytokines. Levels of IL-4, IL-5, and IL-13 were elevated in sensitized/HA(306-318)-treated mice. Feld1(29-45) administration substantially reduced Th2 cytokine levels in the BAL with more modest reductions in lung tissue homogenates (Fig. 9, a and b). IFN-gamma levels were only marginally elevated in this model and not significantly modulated by Feld1(29-45) treatment. The chemokines CCL11/eotaxin, CCL17/TARC and CCL22/MDC are produced chiefly by epithelial cells and attract CCR3 (receptor for CCL11) and CCR4 (receptor for CCL17 and 22) expressing eosinophils and Th2 cells, respectively (Daugherty et al., 1996; Sallusto et al., 1997; Lloyd et al., 2000). Hence, we determined by ELISA whether these chemokines were altered in mice treated with DR1Feld1. CCL11, CCL17, and CCL22 were elevated in sensitized and challenged mice. i.d. treatment with Feld1(29-45) significantly reduced levels of these chemokines in the BAL and in lung tissue homogenates compared with HA(306-318) treatment (Fig. 9, c and d). Elevated systemic IgE is also associated with allergic airways disease. In our DR1-tg/Abetao model, total serum IgE and Fel d 1-specific IgE were increased in sensitized and challenged mice. Treatment with Feld1(29-45) but not HA(306-318) significantly reduced levels of IgE in the serum (Fig. 9, e and f). Thus, i.d. treatment with Feld1(29-45) reduced both systemic and local lung Th2 responses to cat allergen.
###end p 26
###begin p 27
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Peptide immunotherapy reduces Th2 cell recruitment to the lung.</bold>
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 432 433 432 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 437 438 437 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 621 622 619 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 658 659 656 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 714 723 712 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 766 773 764 771 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 823 824 819 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 944 953 940 949 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 977 984 973 980 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 1014 1015 1010 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 216 220 <span type="species:ncbi:10090">Mice</span>
###xml 294 299 <span type="species:ncbi:10090">mouse</span>
###xml 313 318 <span type="species:ncbi:10090">mouse</span>
###xml 682 686 <span type="species:ncbi:10090">mice</span>
###xml 782 786 <span type="species:ncbi:10090">mice</span>
###xml 829 833 <span type="species:ncbi:10090">mice</span>
Peptide immunotherapy reduces Th2 cell recruitment to the lung. T1ST2+ (a Th2 cell phenotypic marker) cells were measured in the BAL (a), lung tissue digest (b), and peri-bronchial lymph nodes (c) by flow cytometry. Mice were sacrificed at day 61, and cells were isolated and stained with anti-mouse CD4 and anti-mouse T1ST2 as described in the Materials and methods. For BAL and lung tissue digest, data are expressed as mean T1ST2+/CD4+ cell numbers +/- SEM by multiplying the percentage expression on live cells by the total cell counts. For lymph node cells, data shown are the percentage of expression within the CD4+ population. T1ST2 expression on CD4+ cells of unsensitized mice (white bars), sensitized/HA(306-318)-treated (black bars), and sensitized/Feld1(29-45)-treated mice (gray bars). Data are mean +/- SEM. n = 5 mice/group and data are representative of 4 independent experiments. *, P < 0.05 and **, P < 0.01 for sensitized/HA(306-318) versus sensitized/Feld1(29-45) treated groups, Mann-Whitney U test.
###end p 27
###begin p 28
###xml 61 62 61 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 76 77 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 121 0 121 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Peptide immunotherapy reduces proportions of lung tissue IL-4<sup>+</sup> and IL-5<sup>+</sup> CD4<sup>+</sup> cells after antigen restimulation in vitro.</bold>
###xml 377 378 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 388 389 384 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 419 420 415 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 430 431 426 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 547 548 543 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 638 639 634 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 122 126 <span type="species:ncbi:10090">Mice</span>
Peptide immunotherapy reduces proportions of lung tissue IL-4+ and IL-5+ CD4+ cells after antigen restimulation in vitro. Mice were sacrificed at day 61 and cells from collagenase digests of lung tissue were restimulated in vitro with 10 microg/ml rFel d 1 for 6 d. Cells were further stimulated with PMA/ionomycin in the presence of brefeldin A for 4 h. (a) Percentage of IL-4+ cells CD4+ cells. (b) Percentage of IL-5+ cells CD4+ cells are shown with isotype control staining subtracted. Individual data points are shown with medians indicated. n = 6-10/group from 2 independent experiments. P values were determined using Mann-Whitney U test.
###end p 28
###begin p 29
###xml 0 93 0 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Peptide immunotherapy inhibits levels of Th2 cytokines, Th2 chemokines, and serum IgE levels.</bold>
###xml 952 953 942 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1073 1082 1063 1072 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 1111 1116 1101 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1</italic>
###xml 1111 1116 1101 1106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>Feld1</italic></sup>
###xml 94 98 <span type="species:ncbi:10090">Mice</span>
###xml 958 962 <span type="species:ncbi:10090">mice</span>
###xml 1125 1129 <span type="species:ncbi:10090">mice</span>
Peptide immunotherapy inhibits levels of Th2 cytokines, Th2 chemokines, and serum IgE levels. Mice were sacrificed at day 61. Serum was obtained by cardiac puncture, BAL was performed to obtain BAL fluid, and single lung lobes were harvested and enzymatically digested. (a) BAL fluid and (b) lung digest homogenate cytokines IL-4, IL-5, IL-13, and IFN-gamma were measured by ELISA according to manufacturer's protocols. Th2 chemokines CCL11/eotaxin, CCL17/TARC, and CCL22/MDC in BAL fluid (c) and lung digest homogenates (d) were measured by ELISA according to the manufacturer's protocols. Total IgE in serum samples (e) was quantified by ELISA using paired antibodies according to the manufacturer's protocol. Levels of Fel d 1-specific IgE (f) were measured in serum by coating plates with recombinant Fel d 1 (5 microg/ml), incubating with serum samples, and detecting bound IgE with chromogen-labeled anti-IgE. Data are expressed as mean +/- SEM. n = 5 mice/group, and are representative of three independent experiments. *, P < 0.05 and **, P < 0.01 for sensitized/HA(306-318) compared with sensitized/DR1Feld1-treated mice.
###end p 29
###begin title 30
###xml 64 71 64 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
Neutralization of IL-10 activity during immunotherapy with Feld1(29-45) reverses peptide-induced tolerance
###end title 30
###begin p 31
###xml 20 27 20 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 148 149 148 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 153 154 153 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 574 581 574 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 693 702 693 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig10">Fig. 10 a</xref>
###xml 906 915 906 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig10">Fig. 10 b</xref>
###xml 1004 1013 1004 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig10">Fig. 10 c</xref>
###xml 1046 1055 1046 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig10">Fig. 10 d</xref>
###xml 1078 1085 1078 1085 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 1182 1183 1182 1183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1186 1198 1186 1198 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1(29&#8211;45)</sub>
###xml 1206 1207 1206 1207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1215 1221 1215 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4</xref>
###xml 1302 1303 1302 1303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1306 1318 1306 1318 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1(29&#8211;45)</sub>
###xml 1326 1327 1326 1327 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1342 1351 1342 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig10">Fig. 10 e</xref>
###xml 1543 1552 1543 1552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig10">Fig. 10 f</xref>
###xml 36 39 <span type="species:ncbi:9685">cat</span>
###xml 348 351 <span type="species:ncbi:9685">cat</span>
###xml 655 659 <span type="species:ncbi:10090">mice</span>
###xml 1407 1411 <span type="species:ncbi:10090">mice</span>
###xml 1537 1541 <span type="species:ncbi:10090">mice</span>
Treatment with Feld1(29-45) reduced cat allergen-stimulated Th2 responses systemically and in the lung. Treatment was associated with elevated IL-10+ CD4+ T cells in lung tissue. To determine whether peptide immunotherapy in this model was IL-10 dependent, we neutralized IL-10 activity in vivo beginning at the time of peptide-treatment and until cat allergen rechallenge. In vivo administration of anti-IL-10 receptor (R) antibody effectively reversed peptide-induced tolerance. Anti-IL-10R treatment increased airway resistance, abrogating the therapeutic effect of Feld1(29-45) on lung function, but was without effect on airway resistance in control mice, which remained at basal levels (Fig. 10 a). In addition to reversal of peptide therapy effects on lung function, anti-IL-10R treatment was associated with exacerbation of Th2 lung inflammation. Significant increases in BAL and lung eosinophils (Fig. 10 b), together with increased numbers of T cells expressing the Th2 cytokines IL-4 or IL-5 (Fig. 10 c) and the Th2 cell marker T1ST2 (Fig. 10 d), were observed. Feld1(29-45) therapy was shown to reduce the numbers of proliferating Fel d 1-specific T cells, including CD4+DR1Feld1(29-45)tetramer+ cells (Fig. 4). Anti-IL-10R treatment reversed this effect and restored Fel d 1-stimulated CD4+DR1Feld1(29-45)tetramer+ cell numbers (Fig. 10 e). Finally, neutralization of IL-10R in peptide-treated mice also resulted in an elevated systemic Th2 response, as shown by significantly higher total IgE levels in anti-IL-10R-treated mice (Fig. 10 f). Collectively, these data indicate that the mechanism of low-dose peptide immunotherapy is IL-10-dependent in a wide range of physiological, cellular, and humoral parameters.
###end p 31
###begin p 32
###xml 4 11 4 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 0 56 0 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld<sup>(29&#8211;45)</sup> peptide immunotherapy is dependent on IL-10.</bold>
###xml 122 129 122 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 154 160 154 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2</xref>
###xml 855 856 851 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 859 860 855 856 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1013 1014 1009 1010 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1017 1018 1013 1014 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1023 1024 1019 1020 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1119 1120 1115 1116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1125 1127 1121 1123 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sub>
###xml 1131 1143 1127 1139 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1(29&#8211;45)</sub>
###xml 1152 1153 1148 1149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1201 1207 1197 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4</xref>
###xml 1375 1376 1369 1370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1496 1503 1486 1493 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 57 61 <span type="species:ncbi:10090">Mice</span>
###xml 162 166 <span type="species:ncbi:10090">Mice</span>
###xml 304 308 <span type="species:ncbi:10090">Mice</span>
###xml 332 335 <span type="species:ncbi:9685">cat</span>
###xml 407 411 <span type="species:ncbi:10090">mice</span>
###xml 478 482 <span type="species:ncbi:10090">mice</span>
###xml 636 640 <span type="species:ncbi:10090">mice</span>
###xml 1160 1165 <span type="species:ncbi:10090">mouse</span>
###xml 1384 1388 <span type="species:ncbi:10090">mice</span>
###xml 1514 1518 <span type="species:ncbi:10090">mice</span>
Feld(29-45) peptide immunotherapy is dependent on IL-10. Mice were sensitized, allergen-challenged, and treated with Feld1(29-45) peptide as described in Fig. 2. Mice were then treated with neutralizing antibody to the IL-10 receptor (alphaIL-10R) or an isotype control antibody (Ig) weekly from day 25. Mice were rechallenged with cat allergen extract (days 59 and 60), lung function was analyzed, and the mice were sacrificed (day 61) for tissue harvest. Unsensitized control mice received PBS in alum and were challenged in the same manner as sensitized animals. Airway resistance (a) was measured in anesthetized and tracheotomized mice. BALF and lung tissue cells were isolated as described in the Materials and methods. Eosinophil numbers in BAL and lung tissue (b) were determined after differential counting of Wright-Giemsa-stained cytospins. CD3+CD4+ T cells in lung digests expressing IL-4 and IL-5 (c) were evaluated by flow cytometry of light-scatter lymphocyte-gated cells. Numbers of Th2 cells (CD3+CD4+T1ST2+; d) in the BAL and lung tissue were determined by flow cytometry. Numbers of proliferating CD4+ CFSElo DR1Feld1(29-45) tetramer+ cells/mouse (e) were evaluated as described in Fig. 4. Total serum IgE (f) was quantified as described in the Materials and methods. Data are expressed as mean +/- SEM or as individual data points with medians indicated. n = 5-12 mice/group. *, P < 0.05; **, P < 0.01; and ***, P < 0.001 for Ig-treated compared with alphaIL-10R-treated Feld1(29-45)-tolerized mice. Two independent experiments were performed, with some outcomes performed in one or other of the experiments. Data in a, c, and e represent a single experiment; those in panels b, d, and f represent two experiments.
###end p 32
###begin title 33
DISCUSSION
###end title 33
###begin p 34
###xml 230 253 230 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">Larche and Wraith, 2005</xref>
###xml 626 647 622 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">Oldfield et al., 2001</xref>
###xml 649 670 645 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Oldfield et al., 2002</xref>
###xml 672 695 668 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">Alexander et al., 2005a</xref>
###xml 697 720 693 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">Alexander et al., 2005b</xref>
###xml 856 857 852 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 878 898 874 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib41">Verhoef et al., 2005</xref>
###xml 76 81 <span type="species:ncbi:10090">mouse</span>
Peptide immunotherapy with CD4 T cell epitopes has been used extensively in mouse models to prevent and ameliorate antigen-specific inflammatory responses and is the subject of current clinical trials in allergy and autoimmunity (Larche and Wraith, 2005). Improved understanding of mechanisms is likely to significantly improve efficacy. In our clinical studies, Fel d 1 peptides were delivered i.d., at low dose, to redirect allergen-specific responses, decrease symptoms, and reduce inflammation. Systemic doses of peptide as low as 5 microg reduced skin allergen sensitivity and proinflammatory PBMC responses to allergen (Oldfield et al., 2001; Oldfield et al., 2002; Alexander et al., 2005a; Alexander et al., 2005b). Reduced proliferative responses to allergen were associated with increased IL-10 production from PBMC and induction of functional CD4+ regulatory T cells (Verhoef et al., 2005).
###end p 34
###begin p 35
###xml 549 574 549 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">Holan and Mitchison, 1983</xref>
###xml 1420 1432 1420 1432 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1(29&#8211;45)</sub>
###xml 1440 1441 1440 1441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1460 1463 1460 1463 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 2154 2155 2154 2155 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2159 2160 2159 2160 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2181 2201 2181 2201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">Kearley et al., 2005</xref>
###xml 2323 2339 2323 2339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">Qin et al., 1993</xref>
###xml 755 760 <span type="species:ncbi:9606">human</span>
###xml 794 799 <span type="species:ncbi:10090">mouse</span>
###xml 889 894 <span type="species:ncbi:9606">human</span>
###xml 907 911 <span type="species:ncbi:10090">Mice</span>
###xml 1017 1022 <span type="species:ncbi:9606">human</span>
###xml 1137 1141 <span type="species:ncbi:10090">mice</span>
###xml 1160 1165 <span type="species:ncbi:9606">human</span>
###xml 1660 1665 <span type="species:ncbi:10090">mouse</span>
To define the immunological mechanisms underlying the effects of peptide immunotherapy, we performed a detailed analysis of peptide-specific responses in allergic asthmatic subjects treated with a therapeutic peptide vaccine or with placebo. Peptide treatment reduced proliferative and cytokine responses to both treatment and nontreatment peptides, which is indicative of linked epitope suppression, a process through which cells rendered tolerant to one epitope suppress the function of cells specific for other epitopes within the same molecule (Holan and Mitchison, 1983). To determine the functional effects of peptide immunotherapy on T cells from the lung parenchyma and airways, which are more relevant to clinical asthma but cannot be studied in human volunteers, we generated a novel mouse model of peptide immunotherapy. The model was specifically designed to closely mimic our human experience. Mice were treated with a single Fel d 1 peptide, which forms part of the therapeutic clinical vaccine used in human studies. Presentation of the peptide to T cells was restricted by the only MHC class II molecule expressed by the mice, the product of a human HLA-DR1 transgene. Using this novel model we were able for the first time to directly track T cell responses to the treatment peptide using HLA-DR1 tetramer reagents. Tetramer analysis revealed reduced antigen-specific proliferative responses of both DR1Feld1(29-45)tetramer+ cells and tetramerneg cells supporting the observation of linked epitope suppression in the clinical study. Given the marked reduction in lung inflammation and decreases in Th2 responses after peptide treatment in the mouse model, it is clear that the peptide-specific T cell population was capable of down-regulating an established inflammatory response driven by multiple T cell epitopes. Indeed, in this model, targeting of a relatively rare population of peptide-specific T cells was associated with the production of IL-10 by a much larger proportion of the T cell pool. Similar induction of IL-10-producing "bystander" T cells was recently reported in a related model after transfer of antigen-specific CD4+CD25+ regulatory T cells (Kearley et al., 2005). "Infectious" expansion of IL-10-producing T cell populations has been described previously in other disease scenarios (Qin et al., 1993).
###end p 35
###begin p 36
###xml 75 76 75 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 375 376 375 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Peptide therapy markedly increased BAL levels of IL-10 and numbers of IL-10+ T cells in lung tissue, the latter increasing threefold. Lung digest T cells cultured for 7 d with recombinant allergen showed lower levels of proliferation after Fel d 1 peptide treatment compared with control peptide. This may have been caused by suppressive effects of increased numbers of IL-10+ T cells, and/or caused by a reduction in the numbers of allergen-specific T cells through clonal deletion.
###end p 36
###begin p 37
###xml 219 241 219 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">Akdis and Blaser, 1999</xref>
###xml 243 259 243 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">Raz et al., 2001</xref>
###xml 261 282 261 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Oldfield et al., 2002</xref>
###xml 284 304 284 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">Prakken et al., 2004</xref>
###xml 312 313 312 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 453 479 453 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">Bellinghausen et al., 1997</xref>
###xml 481 500 481 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">Nasser et al., 2001</xref>
###xml 502 525 502 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">Nouri-Aria et al., 2004</xref>
###xml 646 664 646 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">Akdis et al., 2004</xref>
###xml 803 804 803 804 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 808 809 808 809 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 900 920 900 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">Kearley et al., 2005</xref>
###xml 1062 1080 1062 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Henry et al., 2008</xref>
###xml 1183 1198 1183 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">Oh et al., 2002</xref>
###xml 1457 1464 1457 1464 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 1015 1019 <span type="species:ncbi:10090">mice</span>
PBMCs from allergen peptide-treated subjects, and heat shock protein peptide-treated subjects with type I diabetes and rheumatoid arthritis, demonstrated enhanced levels of antigen-stimulated IL-10 production in vitro (Akdis and Blaser, 1999; Raz et al., 2001; Oldfield et al., 2002; Prakken et al., 2004). IL-10+ cells have been found to increase in number in blood and tissues taken in clinical studies of grass pollen and insect venom immunotherapy (Bellinghausen et al., 1997; Nasser et al., 2001; Nouri-Aria et al., 2004) and a higher frequency of IL-10-secreting T cells is found in peripheral blood of nonatopic versus atopic individuals (Akdis et al., 2004). Adoptive transfer of IL-10-secreting cells has been shown to ameliorate allergic airway inflammation. We have shown that transfer of CD4+CD25+ regulatory T cells suppresses allergic lung inflammation by an IL-10-dependent mechanism (Kearley et al., 2005). Furthermore, IL-10-transduced dendritic cells down-regulate allergic airway inflammation in mice by induction of IL-10-expressing T cells (Henry et al., 2008), and OVA-specific T cells engineered to express IL-10 also inhibit Th2-induced AHR and inflammation (Oh et al., 2002). In this study, neutralization of IL-10 activity via blockade of IL-10R reversed peptide-induced tolerance, as shown by lung function analysis, elevation of lung and systemic Th2 responses, and reversal of peptide treatment effects on proliferation of Feld1(29-45)-specific T cells. These results specifically demonstrate the IL-10 dependence of peptide therapy in this model, which does not rely on the transfer of manipulated cells.
###end p 37
###begin p 38
###xml 51 63 51 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1(29&#8211;45)</sub>
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
We did not observe an increase in the number of DR1Feld1(29-45)tetramer+ nondividing cells which would have been expected had they been anergized. Thus, we further conclude that peptide therapy does not result in the induction of anergy in the target T cell population, a possibility we have been thus far unable to exclude in clinical studies.
###end p 38
###begin p 39
###xml 116 134 116 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">Chai et al. (2004)</xref>
###xml 256 288 252 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">Apostolou and Von Boehmer (2004)</xref>
###xml 339 340 335 336 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 344 345 340 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 650 673 642 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Kretschmer et al., 2005</xref>
###xml 45 50 <span type="species:ncbi:10090">mouse</span>
Resolution of allergic airway disease in our mouse model was achieved with administration of only a single peptide. Chai et al. (2004) prevented graft rejection by prophylactic administration of 9 microg (3 administrations) of peptide intranasally (i.n.). Apostolou and Von Boehmer (2004) induced de novo conversion of naive T cells to CD4+CD25+ antigen-specific regulatory cells through chronic exposure (10 microg/d for 14 d) to peptide. By directly targeting dendritic cells with an influenza peptide integrated into an antibody to DEC-205, Kretschmer et al. generated antigen-specific regulatory T cells with the equivalent of 500 pg of epitope (Kretschmer et al., 2005). Here we report the induction of antigen-specific tolerance and resolution of inflammation after the single administration of 1 microg of peptide without adjuvant or cell-targeting strategy. Thus, ultra low-dose delivery of CD4 T cell epitopes can induce T cells with regulatory function that are capable of reversing existing pathology.
###end p 39
###begin p 40
###xml 273 280 269 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 539 540 535 536 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Using lavage and whole lung tissue, we demonstrated a marked reduction in airway and tissue eosinophilia and reduced in situ Th2 inflammation. BAL and lung tissue IL-4, IL-5, and IL-13 cytokine production was reduced. Local IFN-gamma production was not elevated after Feld1(29-45) treatment, suggesting that peptide therapy did not result in deviation from a Th2 to a Th1 response. Levels of the Th2-associated chemokines CCL11, CCL17, and CCL22 were also significantly decreased. Possibly as a direct result of this, we observed fewer CD4+ T cells expressing IL-4 and IL-5 and reduced recruitment of Th2 cells to lung tissue and BAL after peptide treatment.
###end p 40
###begin p 41
###xml 102 103 99 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 130 131 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 215 232 212 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Chen et al., 2003</xref>
###xml 234 265 231 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">Apostolou and Von Boehmer, 2004</xref>
###xml 577 597 568 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">Kearley et al., 2005</xref>
###xml 658 659 649 650 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 663 664 654 655 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 685 702 676 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">Hori et al., 2003</xref>
###xml 753 754 744 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 888 889 879 880 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 959 960 950 951 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 964 965 955 956 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1087 1105 1078 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">Smith et al., 2004</xref>
TGF-beta has been implicated in T cell regulation of immune responses through conversion of naive CD25- T cells to regulatory CD25+ cells through induction of Foxp3 expression and reduction of T cell proliferation (Chen et al., 2003; Apostolou and Von Boehmer, 2004). However, in this study, we found no change in levels of active TGF-beta1 in BAL or lung tissue homogenates after peptide challenge. This implies that TGF-beta does not have a significant role in suppression of pulmonary pathophysiology in this model. We have described similar findings in another lung model (Kearley et al., 2005). Because Foxp3 expression is thought to be a marker for CD4+CD25+ regulatory T cells (Hori et al., 2003) we measured intracellular Foxp3 expression in CD4+ T cells isolated from BAL, lung tissue, and peribronchial lymph nodes. Peptide treatment did not result in increased numbers of Foxp3+ cells in any of these tissues. These data may discount a role for CD4+CD25+ regulatory T cells in peptide-directed resolution of pathophysiology, in agreement with our published clinical findings (Smith et al., 2004), but importantly they highlight a role for IL-10-secreting regulatory cells.
###end p 41
###begin p 42
###xml 96 101 <span type="species:ncbi:10090">mouse</span>
###xml 208 213 <span type="species:ncbi:9606">human</span>
###xml 214 217 <span type="species:ncbi:9685">cat</span>
###xml 410 414 <span type="species:ncbi:10090">mice</span>
###xml 1142 1147 <span type="species:ncbi:10090">mouse</span>
In summary, our data indicate that peptide immunotherapy ameliorates allergic inflammation in a mouse model via an IL-10-dependent mechanism and substantially reduces clinical surrogate markers of allergy in human cat allergic asthmatics through a process involving linked epitope suppression associated with induction of IL-10. No evidence for the induction of clonal T cell anergy was obtained. Treatment of mice was associated with reduced eosinophilia and mucus production, improved lung function, reduced Th2 cytokine and chemokine levels, lower total and specific IgE, and reduced numbers of Th2 cells infiltrating the lung tissue and BAL. Moreover, we demonstrate, for the first time, the direct effect of peptide administration on functional responses of lung parenchymal T cells specific for the treatment peptide using MHC class II tetramers. The percentage of IL-10-producing T cells was markedly enhanced in the lung after peptide therapy and was substantially greater than the percentage of cells specific for the treatment peptide, an observation that is reminiscent of infectious tolerance. Finally, tolerance induction in the mouse model appeared to be independent of TGF-beta and Foxp3 expression. These studies further our understanding of mechanisms of peptide-induced tolerance in allergic asthma. These results will inform the design and evaluation of peptide interventions to ameliorate chronic allergic and autoimmune diseases.
###end p 42
###begin title 43
MATERIALS AND METHODS
###end title 43
###begin title 44
Randomized, double-blind, placebo-controlled trial of peptide immunotherapy in allergic asthma
###end title 44
###begin p 45
###xml 80 101 80 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Oldfield et al., 2002</xref>
###xml 445 446 445 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 672 673 668 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 816 817 812 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 528 531 <span type="species:ncbi:9685">cat</span>
The protocol and clinical outcomes of this trial have been reported previously (Oldfield et al., 2002). The study was approved by the Royal Brompton and Harefield National Health Service Trust Ethics Committee. All subjects gave written informed consent. For this study, peripheral blood samples were obtained before and after therapy. PBMCs were isolated and cryopreserved. PBMCs were cultured in 96-well plates for 6 d at a concentration of 106 cells/ml in the presence of 100 microg/ml of each peptide, with medium alone and cat dander allergen extract acting as controls. 12 replicate wells were cultured for each condition. Proliferative responses were evaluated by [3H]thymidine incorporation. For cytokine analysis, cells were cultured with medium, individual peptides or allergen at a concentration of 5 x 106 cells/ml. Supernatants were harvested at 6 d and frozen. Cytokine production was measured by ELISA (Pelikine).
###end p 45
###begin title 46
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
Transgenic mice
###end title 46
###begin p 47
###xml 94 114 94 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Altmann et al., 1995</xref>
###xml 302 303 299 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 395 396 389 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 29 44 <span type="species:ncbi:10090">transgenic mice</span>
###xml 165 170 <span type="species:ncbi:10090">mouse</span>
###xml 207 212 <span type="species:ncbi:10090">mouse</span>
###xml 233 248 <span type="species:ncbi:10090">transgenic mice</span>
###xml 304 308 <span type="species:ncbi:10090">mice</span>
###xml 369 374 <span type="species:ncbi:10090">mouse</span>
###xml 545 549 <span type="species:ncbi:10090">mice</span>
HLA-DR1 (DRA*0101/DRB1*0101) transgenic mice on a FVB/N background were described previously (Altmann et al., 1995). DR1 expression in these animals mirrors that of mouse MHC II, and antigen presentation to mouse T cells occurs. DR1 transgenic mice were crossed for eight generations with C57BL/6 Abetao mice to yield animals on a C57BL/6 background with no endogenous mouse MHC II (DR1-tg/Abetao). Polymerase chain reaction was routinely used to confirm the presence of HLA-DRA1*0101 and HLA-DRB1*0101 and the absence of endogenous H2-Abeta in mice. 8-12-wk-old age, sex, and weight-matched animals were used in all experiments. All animal procedures were approved by the UK Home Office. UK Home Office regulations for animal welfare, based on the Animals (Scientific Procedures) Act 1986, were strictly observed.
###end p 47
###begin title 48
Allergens and peptides
###end title 48
###begin p 49
###xml 58 79 58 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">Gronlund et al., 2003</xref>
###xml 648 655 648 655 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 758 779 758 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">Haselden et al., 1999</xref>
###xml 792 801 792 801 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 912 930 912 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">Stern et al., 1994</xref>
###xml 82 85 <span type="species:ncbi:9685">Cat</span>
###xml 153 156 <span type="species:ncbi:9685">cat</span>
###xml 631 636 <span type="species:ncbi:10090">mouse</span>
Recombinant Fel d 1 was prepared as described previously (Gronlund et al., 2003). Cat allergen extract (predominantly Fel d 1, but also containing other cat proteins) was obtained from Laboratorios Leti. Peptide sequences for the clinical study were: Fel d 1 chain 1 (1-17) EICPAVKRDVDLFLTGT, (12-28) FLTGTPDEYVEQVAQY, (23-38) EQVAQYKALPVVLENA, (29-45) KALPVVLENARILKNCV, (39-55) RILKNCVDAKMTEEDKE, (48-63) KMTEEDKENALSLLDK, (54-69) KENALSVLDKIYTSPL, Fel d 1 chain 2 (29-44) LTKVNATEPERTAMKK, (40-55) TAMKKIQDCYVENGLI, (56-71) SRVLDGLVMTTISSSK, (67-82) ISSSKDCMGEAVQNTV, and (77-92) AVQNTVEDLKLNTLGR. The treatment peptide for the mouse model Feld1(29-45) (residues 29-45 of Fel d 1 chain 1; KALPVVLENARILKNCV) was previously shown to be HLA-DR1 restricted (Haselden et al., 1999). Peptide HA(306-318) (residues 306-318 of influenza virus hemagglutinin; PKYVKQNTLKLAT) was used as a DR1-binding peptide control (Stern et al., 1994). Peptides were synthesized by F-moc chemistry at the Peptide Synthesis Unit, Medical Research Council Clinical Sciences Centre, Imperial College, London, UK.
###end p 49
###begin title 50
Allergen-induced airway inflammation and peptide-induced tolerance
###end title 50
###begin p 51
###xml 39 46 39 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 98 99 95 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 267 273 264 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2</xref>
###xml 879 886 856 863 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(29&#8211;45)</sup>
###xml 910 919 887 896 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(306&#8211;318)</sup>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
###xml 169 172 <span type="species:ncbi:9685">cat</span>
###xml 276 280 <span type="species:ncbi:10090">Mice</span>
###xml 331 336 <span type="species:ncbi:10090">mouse</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 481 485 <span type="species:ncbi:10090">Mice</span>
###xml 576 579 <span type="species:ncbi:9685">cat</span>
###xml 686 690 <span type="species:ncbi:10090">mice</span>
###xml 799 803 <span type="species:ncbi:10090">mice</span>
###xml 972 976 <span type="species:ncbi:10090">mice</span>
###xml 1110 1114 <span type="species:ncbi:10090">mice</span>
###xml 1147 1150 <span type="species:ncbi:9685">cat</span>
###xml 1345 1349 <span type="species:ncbi:10090">mice</span>
Before therapeutic treatment with Feld1(29-45) allergic airway disease was induced in DR1-tg/Abetao mice by sensitization to Fel d 1, followed by inhaled challenge with cat allergen extract to localize inflammation to the lung tissues (experiment flow chart given in Fig. 2). Mice were sensitized by injection of 10 microg Fel d 1/mouse in 0.2 ml of alum (Au-Gel-S; Serva Electrophoresis) i.p. on days 0 and 14. Unsensitized (control) mice received the same volume of PBS in alum. Mice were challenged i.n. under halothane anesthesia, with 25 microl PBS containing 250 microg cat allergen extract or 25 microl PBS alone in the case of unsensitized controls on days 22, 23, and 24. Some mice were sacrificed on day 25 to confirm the presence of eosinophilic lung inflammation. To induce tolerance in mice with established airways disease, a single i.d. injection of 1 microg Feld1(29-45) (or peptide control, HA(306-318)) was administered on day 25. In select experiments, mice were treated weekly with 250 microg of anti-IL-10R antibody (1B1.3), or isotype control antibody on days 32, 39, 46, 53, and 58. All mice were challenged again i.n. with cat allergen extract on day 59 and 60. Immediately before the second of these challenges, AHR was assessed. 24 h after the last challenge, airway resistance and dynamic compliance were analyzed and mice were killed by exsanguination under terminal anesthesia. Blood, BAL, lung tissue, and draining lymph nodes were taken for analysis.
###end p 51
###begin title 52
Measurement of airway function
###end title 52
###begin p 53
###xml 240 262 240 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Hamelmann et al., 1997</xref>
###xml 649 668 649 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">Martin et al., 1988</xref>
###xml 486 490 <span type="species:ncbi:10090">mice</span>
AHR was measured at day 60 by recording respiratory pressure curves by whole-body plethysmography (Buxco Technologies) in response to inhaled methacholine (Sigma-Aldrich) at concentrations of 3-100 mg/ml for 1 min, as described previously (Hamelmann et al., 1997). In select experiments, AHR was also measured at day 25, 24 h after the i.n. challenge on day 24. Penh data were confirmed by direct measurement of lung resistance and dynamic compliance in anesthetized and tracheotomized mice in response to inhaled methacholine at concentrations of 3-100 mg/ml using a Buxco Technologies system in a modified version of previously described methods (Martin et al., 1988).
###end p 53
###begin title 54
Cell recovery
###end title 54
###begin title 55
Airway lumen.
###end title 55
###begin p 56
###xml 43 63 43 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Gonzalo et al., 1996</xref>
###xml 170 171 170 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 258 259 252 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 470 471 464 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
BAL was performed as previously described (Gonzalo et al., 1996). Airways were lavaged three times with 0.4 ml PBS via a tracheal cannula. BAL fluid was centrifuged (700 g, 5 min, 4degreesC), and cells were transferred to slides by cytocentrifugation (5 x 104 cells/slide). Differential cell counts were performed on Wright-Giemsa-stained (Shandon) cytospins. Differential cell counts were determined by counting 8 high power fields (40x magnification; total area 0.5 mm2 per area randomly selected), and dividing this number by the total number of cells per high power field. To obtain absolute numbers of each leukocyte subtype, percentages were multiplied by the total number of cells obtained in the lavage fluid. All differential counts were performed blind and in a randomized order at the end of the study by the same observer.
###end p 56
###begin title 57
Lung parenchyma.
###end title 57
###begin p 58
To disaggregate cells from the lung tissue, one lobe (approximately100 mg) was incubated (37degreesC) for 1 h in digest reagent: 30 mg/ml collagenase (type D; Boehringer Mannheim), 5 mg/ml DNase (type 1; Boehringer Mannheim), 100 U/ml penicillin, and 100 microg/ml streptomycin (Invitrogen) in RPMI 1640(Sigma-Aldrich)/10% FCS. The recovered cells were filtered through a 70-mum nylon sieve (Falcon; Marathon Laboratory Supplies), washed twice, resuspended in RPMI 1640/10% FCS, and counted in a hemocytometer. Cytocentrifuge preparations were made and Wright-Giemsa stained, and differential counts were performed as for BAL.
###end p 58
###begin title 59
Peribronchial lymph nodes.
###end title 59
###begin p 60
###xml 277 278 272 273 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
Draining lymph nodes were dissected out, teased apart, and passed through a 70-mum nylon sieve to generate single-cell suspensions. Cells were resuspended in complete culture medium: RPMI 1640/10% FCS, supplemented with 100 U/ml penicillin, 100 microg/ml streptomycin, and 2 mMl-glutamine (Invitrogen).
###end p 60
###begin title 61
Flow cytometry
###end title 61
###begin title 62
Surface marker staining.
###end title 62
###begin p 63
###xml 216 222 <span type="species:ncbi:9986">rabbit</span>
###xml 305 310 <span type="species:ncbi:10090">mouse</span>
###xml 333 338 <span type="species:ncbi:10090">mouse</span>
Suspensions of cells from lung tissue, lymph nodes, and BAL were stained with fluorescently labeled antibodies in PBS containing 1% FCS and 0.1% sodium azide. To reduce nonspecific binding, cells were incubated with rabbit serum (Sigma-Aldrich) for 15 min before staining. For cell surface staining, anti-mouse CD4-APC (BD) and anti-mouse T1ST2-FITC (Morwell Diagnostics) were used.
###end p 63
###begin title 64
Foxp3 expression.
###end title 64
###begin p 65
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
Intracellular Foxp3 expression in CD4+ cells was detected using an anti-mouse Foxp3 antibody kit (eBioscience) according to the manufacturer's instructions.
###end p 65
###begin title 66
Intracellular cytokines.
###end title 66
###begin p 67
###xml 118 119 114 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 778 802 758 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">Ostroukhova et al., 2004</xref>
###xml 231 234 <span type="species:ncbi:9685">cat</span>
###xml 620 625 <span type="species:ncbi:10090">mouse</span>
###xml 708 713 <span type="species:ncbi:9606">human</span>
###xml 762 767 <span type="species:ncbi:10090">mouse</span>
Cells from lung tissue or lymph nodes were first restimulated with 10 microg/ml recombinant Fel d 1 in vitro at 5 x 105 cells/well in complete RPMI 1640 in round-bottom 96-well plates at 37degreesC for 6 d to preferentially expand cat allergen-specific T cells. Cells were then treated with PMA/ionomycin (10 ng/ml and 1 microg/ml; Merck Biosciences) in the presence of brefeldin A (Sigma-Aldrich) for 4 h. Cells were stained with anti-CD4-APC fixed and permeabilized in 0.5% saponin (Sigma-Aldrich) before intracellular staining with phycoerythrin (PE)-conjugated anti-cytokine antibodies. Cells were stained with anti-mouse IL-4, IL-5, IL-10 and appropriate isotype controls (all from BD). PE-labeled anti-human TGF-beta (IQ Products), which cross reacts with mouse TGF-beta (Ostroukhova et al., 2004), was used to detect surface TGF-beta and, after permeabilization, intracellular TGF-beta.
###end p 67
###begin title 68
CFSE and MHC II tetramer staining.
###end title 68
###begin p 69
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 176 196 176 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib41">Verhoef et al., 2005</xref>
###xml 418 430 414 426 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Feld1[29&#8211;45]</sub>
###xml 516 518 512 514 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A2</sub>
###xml 620 640 616 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">Cameron et al., 2002</xref>
###xml 767 768 763 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1110 1111 1100 1101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 860 865 <span type="species:ncbi:10090">mouse</span>
For the detection of antigen-specific cell proliferation, 2.5 x 106 cells of each sample (pooled/treatment group) were labeled with CFSE (Invitrogen), as previously described (Verhoef et al., 2005). CFSE-treated cells were cultured with 10 microg/ml recombinant Fel d 1, as described in the previosu paragrph, for 6 d before staining with MHC class II (HLA-DR1) tetramers specific for either the treatment peptide (DR1Feld1[29-45]tetramer; peptide KALPVVLENARILKNCV) or an irrelevant control peptide from HLA-A2 (DR1A2tetramer; peptide VGSDWRFLRGYHQYA). Biotinylated DR1 complexes were prepared as described previously (Cameron et al., 2002). Tetramers were formed by stepwise addition of fluorescently labeled streptavidin-PE (Biosource International). Cells (5 x 105) were mixed with DR1 tetramers for 4 h at 37degreesC, chilled for 5 min, stained with anti-mouse CD4-APC for 30 min, washed, and fixed. Flow cytometric analysis was performed using a FACSCalibur cytometer and CellQuest software (BD). A primary gate was set on lymphocytes, as defined by light scatter, and a secondary gate was set on the CD4+ population.
###end p 69
###begin title 70
Cytokine analysis
###end title 70
###begin p 71
###xml 269 270 269 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 813 834 806 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">McMillan et al., 2004</xref>
###xml 338 343 <span type="species:ncbi:10090">mouse</span>
###xml 606 611 <span type="species:ncbi:10090">mouse</span>
###xml 693 698 <span type="species:ncbi:10090">mouse</span>
Cytokines were analyzed in BAL samples and lung tissue homogenate supernatants. Lung tissue was homogenized at 100 mg/ml in HBSS (Invitrogen) in the presence of protease inhibitors (Complete mini protease inhibitor cocktail; Roche). Homogenates were centrifuged at 500 g for 10 min, and supernatants were collected. Paired antibodies for mouse IFN-gamma, IL-4, TGF-beta (BD), IL-5 (Endogen), eotaxin/CCL11, and TARC/CCL17 (R&D Systems) were used in standardized ELISAs according to the manufacturers' protocols. CCL22 levels were measured using a sandwich ELISA generated by coating ELISA plates with anti-mouse MDC (a gift from ICOS Corp.) and detecting bound antibody with biotinylated anti-mouse MDC (R&D Systems) against a standard curve generated using recombinant MDC (R&D Systems) as previously described (McMillan et al., 2004). Kits to measure IL-10 and IL-13 (eBioscience and R&D Systems) were used according to the manufacturers' protocols.
###end p 71
###begin title 72
IgE measurements
###end title 72
###begin p 73
Total IgE in serum samples was quantified by ELISA using paired antibodies according to the manufacturer's protocol (BD). Levels of Fel d 1-specific IgE were measured in serum by coating plates with recombinant Fel d 1 (5 microg/ml), incubating with serum samples, and detecting bound IgE as per the total IgE ELISA.
###end p 73
###begin title 74
Statistical analysis
###end title 74
###begin p 75
###xml 337 338 333 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
For peripheral blood studies, data were tested for normality with a modified Shapiro-Wilks test. Significance of changes within groups was tested with a Wilcoxon's rank sum test. Data are expressed as mean +/- SEM for bar graphs and medians for scatter plots. Statistical significance was accepted when P </= 0.05 using the Mann-Whitney U test.
###end p 75
###begin p 76
###xml 139 142 <span type="species:ncbi:9685">cat</span>
We thank Liying Lu for preparation of DR1-peptide complexes, Lorraine Lawrence for histology, and Enrique Fernandez-Caldas for the gift of cat allergen extract.
###end p 76
###begin p 77
This study was supported by the Medical Research Council (MRC G0100509), National Institutes of Health (R01-AI48833), the Canada Research Chairs program and the Canadian Foundation for Innovation, The Wellcome Trust (057704), the Swedish Research Council, and Asthma UK (05/045). M. Larche was an Asthma UK Senior Research Fellow (2001-2006), C.M. Lloyd is a Wellcome Trust Senior Fellow (057704), J.D. Campbell and K.F. Buckland were supported by the MRC, R.J. Boyton is an MRC Clinician Scientist, J. Kearley is the recipient of a BBSRC CASE studentship, and C.J. Reynolds is funded by the MRC and Asthma UK.
###end p 77
###begin p 78
M. Larche and A.B. Kay are founders, shareholders, and consultants to Circassia Ltd. The authors have no other competing financial interests.
###end p 78
###begin article-title 79
IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy.
###end article-title 79
###begin article-title 80
Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells.
###end article-title 80
###begin article-title 81
###xml 96 99 <span type="species:ncbi:9685">cat</span>
The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects.
###end article-title 81
###begin article-title 82
###xml 172 175 <span type="species:ncbi:9685">cat</span>
Fel d 1-derived T cell peptide therapy induces recruitment of CD4CD25; CD4 interferon-gamma T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects.
###end article-title 82
###begin article-title 83
###xml 30 45 <span type="species:ncbi:10090">transgenic mice</span>
###xml 49 54 <span type="species:ncbi:9606">human</span>
###xml 126 131 <span type="species:ncbi:9606">human</span>
The T cell response of HLA-DR transgenic mice to human myelin basic protein and other antigens in the presence and absence of human CD4.
###end article-title 83
###begin article-title 84
In vivo instruction of suppressor commitment in naive T cells.
###end article-title 84
###begin article-title 85
Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects.
###end article-title 85
###begin article-title 86
Labeling antigen-specific CD4(+) T cells with class II MHC oligomers.
###end article-title 86
###begin article-title 87
Transplantation tolerance induced by intranasal administration of HY peptides.
###end article-title 87
###begin article-title 88
###xml 28 29 28 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.
###end article-title 88
###begin article-title 89
Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses.
###end article-title 89
###begin article-title 90
###xml 49 54 <span type="species:ncbi:9606">human</span>
Cloning, expression, and characterization of the human eosinophil eotaxin receptor.
###end article-title 90
###begin article-title 91
###xml 40 46 <span type="species:ncbi:10090">murine</span>
Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors.
###end article-title 91
###begin article-title 92
###xml 57 60 <span type="species:ncbi:9685">cat</span>
###xml 130 146 <span type="species:ncbi:562">Escherichia coli</span>
Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli.
###end article-title 92
###begin article-title 93
###xml 61 65 <span type="species:ncbi:10090">mice</span>
Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography.
###end article-title 93
###begin article-title 94
Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions.
###end article-title 94
###begin article-title 95
Dendritic cells genetically engineered to express IL-10 induce long-lasting antigen-specific tolerance in experimental asthma.
###end article-title 95
###begin article-title 96
Haplotype-specific suppressor T cells mediating linked suppression of immune responses elicited by third-party H-2 alloantigens.
###end article-title 96
###begin article-title 97
Control of regulatory T cell development by the transcription factor Foxp3.
###end article-title 97
###begin article-title 98
Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent.
###end article-title 98
###begin article-title 99
Inducing and expanding regulatory T cell populations by foreign antigen.
###end article-title 99
###begin article-title 100
Peptide-based therapeutic vaccines for allergic and autoimmune diseases.
###end article-title 100
###begin article-title 101
CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo.
###end article-title 101
###begin article-title 102
###xml 58 63 <span type="species:ncbi:10090">mouse</span>
Pulmonary responses to bronchoconstrictor agonists in the mouse.
###end article-title 102
###begin article-title 103
Matrix metalloproteinase-9 deficiency results in enhanced allergen-induced airway inflammation.
###end article-title 103
###begin article-title 104
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy.
###end article-title 104
###begin article-title 105
Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.
###end article-title 105
###begin article-title 106
CD4 T-helper cells engineered to produce IL-10 prevent allergen-induced airway hyperreactivity and inflammation.
###end article-title 106
###begin article-title 107
Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects.
###end article-title 107
###begin article-title 108
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 118 122 <span type="species:ncbi:9685">cats</span>
Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial.
###end article-title 108
###begin article-title 109
Tolerance induced by inhaled antigen involves CD4(+) T cells expressing membrane-bound TGF-beta and FOXP3.
###end article-title 109
###begin article-title 110
Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis.
###end article-title 110
###begin article-title 111
"Infectious" transplantation tolerance.
###end article-title 111
###begin article-title 112
Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.
###end article-title 112
###begin article-title 113
###xml 53 58 <span type="species:ncbi:9606">human</span>
Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells.
###end article-title 113
###begin article-title 114
T cell anergy.
###end article-title 114
###begin article-title 115
###xml 0 3 <span type="species:ncbi:9685">Cat</span>
###xml 67 70 <span type="species:ncbi:9685">cat</span>
Cat allergen peptide immunotherapy reduces CD4 T cell responses to cat allergen but does not alter suppression by CD4 CD25 T cells: a double-blind placebo-controlled study.
###end article-title 115
###begin article-title 116
###xml 25 30 <span type="species:ncbi:9606">human</span>
Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide.
###end article-title 116
###begin article-title 117
Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo.
###end article-title 117
###begin article-title 118
Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy.
###end article-title 118
###begin article-title 119
T cell epitope immunotherapy induces a CD4(+) T cell population with regulatory activity.
###end article-title 119
###begin p 120
Abbreviations used: AHR, airway hyperreactivity; BAL, bronchoalveolar lavage; i.d., intradermal(ly); i.n., intranasal(ly); PE, phycoerythrin.
###end p 120

